Budesonide / formoterol fumarate (SYMBICORT) vs mometasone furoate/formoterol fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor; Beta-2 adrenergic receptor · full Asthma pipeline

Budesonide / formoterol fumarate (SYMBICORT)

Marketed by AstraZeneca

Approved in Asthmacombination (ICS + LABA)
Partial signal

NCT00646321 · Phase 3 · completed

The study was randomized and double-blind, used budesonide as an active comparator, and planned to enroll 540 participants. Its primary endpoint was change in evening peak expiratory flow, a lung-function surrogate rather than a hard clinical or endoscopic outcome, and no primary endpoint results are posted.

Reported efficacy

Change in evening PEF (Daily throughout the 12 week treatment period): Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027). (met)

Result source: NCT00646321

mometasone furoate/formoterol fumarate · Dulera / Zenhale

Marketed by Organon and partners

Approved in Asthmasmall molecule combination
Partial signal

NCT00746330 · Phase 2 · completed

The study randomized and quadruple-blinded 32 children to receive the combination, active comparators, and placebo in a crossover design. Its primary endpoint was the surrogate measure of 12-hour FEV1 AUC; although the reported means favored the combination over placebo, statistical significance was not stated, so the result is unclear.

Reported efficacy

Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF (Baseline to Endpoint (12 weeks)); Time-to-first Asthma Exacerbation Over the 26-week Treatment Period for the Comparison of MF/F Versus F: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001. (mixed)

Result source: NCT00383240

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBudesonide /​ formoterol fumarate (SYMBICORT)mometasone furoate/​formoterol fumarate
Severe exacerbations, annualised rate—Not posted · NCT00646321—Not reported
Trough FEV1, change0.2 vs 0.1vs Budesonidewk 12 · n 150NCT00702325—Not reported
ACQ-5, change—Not posted · NCT00646321—Not reported
OCS dose reduction—Not posted · NCT00646321—Not reported

Severe exacerbations, annualised rate

Budesonide /​ formoterol fumarate (SYMBICORT)
—Not posted · NCT00646321
mometasone furoate/​formoterol fumarate
—Not reported

Trough FEV1, change

Budesonide /​ formoterol fumarate (SYMBICORT)
0.2 vs 0.1vs Budesonidewk 12 · n 150NCT00702325
mometasone furoate/​formoterol fumarate
—Not reported

ACQ-5, change

Budesonide /​ formoterol fumarate (SYMBICORT)
—Not posted · NCT00646321
mometasone furoate/​formoterol fumarate
—Not reported

OCS dose reduction

Budesonide /​ formoterol fumarate (SYMBICORT)
—Not posted · NCT00646321
mometasone furoate/​formoterol fumarate
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Budesonide / formoterol fumarate (SYMBICORT): 4 of 4 rows · mometasone furoate/formoterol fumarate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBudesonide /​ formoterol fumarate (SYMBICORT)mometasone furoate/​formoterol fumarate
Dropout rate
24.4%a
NCT00702325 · Phase 4 · registry result, not featured evidence
show 2 more results
0%With Spacer
NCT00536913 · Phase 3 · registry result, not featured evidence
0%Without Spacer
NCT00536913 · Phase 3 · registry result, not featured evidence
—b
NCT00746330 · Phase 2 · combination · Asthma · phase 2
show 6 more results
18.3%200/10 mcg BID
NCT00383240 · Phase 3
19.8%100/10 mcg BID
NCT00383552 · Phase 3
12.5%200/10 mcg MDI BID
NCT01566149 · Phase 3
8%400/10 mcg MDI BID
NCT01566149 · Phase 3
—MF/F MDI With Spacer
NCT01258803 · Phase 2 · registry result, not featured evidence
—MF/F MDI Without Spacer
NCT01258803 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.6%a
NCT00702325 · Phase 4 · registry result, not featured evidence
show 2 more results
—With Spacer
NCT00536913 · Phase 3 · registry result, not featured evidence
—Without Spacer
NCT00536913 · Phase 3 · registry result, not featured evidence
—b
NCT00746330 · Phase 2 · combination · Asthma · phase 2
show 6 more results
2.1%200/10 mcg BID
NCT00383240 · Phase 3
3.8%100/10 mcg BID
NCT00383552 · Phase 3
0%200/10 mcg MDI BID
NCT01566149 · Phase 3
4%400/10 mcg MDI BID
NCT01566149 · Phase 3
—MF/F MDI With Spacer
NCT01258803 · Phase 2 · registry result, not featured evidence
—MF/F MDI Without Spacer
NCT01258803 · Phase 2 · registry result, not featured evidence
Serious AEs
0.6%a
NCT00702325 · Phase 4 · registry result, not featured evidence
show 2 more results
0%With Spacer
NCT00536913 · Phase 3 · registry result, not featured evidence
0%Without Spacer
NCT00536913 · Phase 3 · registry result, not featured evidence
0%b
NCT00746330 · Phase 2 · combination · Asthma · phase 2
show 6 more results
2.6%200/10 mcg BID
NCT00383240 · Phase 3
2.2%100/10 mcg BID
NCT00383552 · Phase 3
0%200/10 mcg MDI BID
NCT01566149 · Phase 3
0%400/10 mcg MDI BID
NCT01566149 · Phase 3
0%MF/F MDI With Spacer
NCT01258803 · Phase 2 · registry result, not featured evidence
0%MF/F MDI Without Spacer
NCT01258803 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
headache 6.4%
nasopharyngitis 5.1%
NCT00702325 · Phase 4 · registry result, not featured evidence
200/10 mcg BIDb
nasopharyngitis 6.3% (placebo 3.6%)
upper respiratory tract infection 5.8% (placebo 8.7%)
headache 4.7% (placebo 3.6%)
NCT00383240 · Phase 3
show 3 more results
100/10 mcg BID
nasopharyngitis 9.3% (placebo 2.7%)
headache 6.6% (placebo 3.7%)
upper respiratory tract infection 5.5% (placebo 6.4%)
NCT00383552 · Phase 3
200/10 mcg MDI BID
upper respiratory tract infection 12.5%
accidental overdose 4.2%
asthma 4.2%
NCT01566149 · Phase 3
400/10 mcg MDI BID
accidental overdose 8%
asthma 8%
cough 8%
NCT01566149 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 6 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Budesonide / formoterol fumarate (SYMBICORT)

FEV1 Trough 0.16 vs 0.07 Budesonide L @ 12wk
absolute change · L
NCT00702325 · Phase 4 · registry result, not featured evidence
Morning PEF 25.34 vs 7.53 Budesonide L @ 12wk
absolute change · L
NCT00702325 · Phase 4 · registry result, not featured evidence
Evening PEF 21.61 vs 7.67 Budesonide L @ 12wk
absolute change · L
NCT00702325 · Phase 4 · registry result, not featured evidence
FVC Change 0.14 vs 0.07 Budesonide L @ 12wk
absolute change · L
NCT00702325 · Phase 4 · registry result, not featured evidence
FEF 25-75% 0.21 vs 0.12 Budesonide L @ 12wk
absolute change · L
NCT00702325 · Phase 4 · registry result, not featured evidence
Asthma Exacerbation Occurrence 37.3% (n=153) vs 45.3% (n=148) Budesonide @ 12wk
event count · % of participants
NCT00702325 · Phase 4 · registry result, not featured evidence · converted to % from 57 Participants as posted
Asthma Symptom -0.35 vs -0.23 Budesonide score @ 12wk
absolute change · score
NCT00702325 · Phase 4 · registry result, not featured evidence
Asthma Symptom Nighttime -0.38 vs -0.26 Budesonide score @ 12wk
absolute change · score
NCT00702325 · Phase 4 · registry result, not featured evidence
Asthma Symptom Daytime -0.33 vs -0.24 Budesonide score @ 12wk
absolute change · score
NCT00702325 · Phase 4 · registry result, not featured evidence
Nocturnal Awakening Free Nights 17.51 vs 11.85 Budesonide count @ 12wk
percent change · count
NCT00702325 · Phase 4 · registry result, not featured evidence
Rescue Medication Use -1.27 vs -0.62 Budesonide per day @ 12wk
absolute change · per day
NCT00702325 · Phase 4 · registry result, not featured evidence
Nighttime Rescue Medication Use -0.79 vs -0.35 Budesonide per day @ 12wk
absolute change · per day
NCT00702325 · Phase 4 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

mometasone furoate/formoterol fumarate

FEV1 AUC0-12h 1.77 vs 1.71 placebo L
absolute change · L
NCT00746330 · Phase 2 · combination · Asthma · phase 2
show 4 more results
0.115 vs -0.009 placebo L
NCT01258803 · Phase 2 · registry result, not featured evidence
0.093 vs -0.009 placebo L
NCT01258803 · Phase 2 · registry result, not featured evidence
0.115 vs 0.097 F DPI L
NCT01258803 · Phase 2 · registry result, not featured evidence
0.093 vs 0.097 F DPI L
NCT01258803 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-12h 3.19 vs 0.51 placebo L @ 12wk200/10 mcg BID
absolute change · L
Endpoint (Change from Baseline)
NCT00383240 · Phase 3
AQLQ Total 0.49 vs -0.01 placebo score @ 26wk200/10 mcg BID
absolute change · score
Change from Baseline to Endpoint (26 weeks)
NCT00383240 · Phase 3
Time to First Exacerbation NA vs 4.3 placebo months @ 26wk200/10 mcg BID
time to event · months
NCT00383240 · Phase 3
show 1 more result
1.49 vs 0.9 placebo months @ 26wk*100/10 mcg BID
NCT00383552 · Phase 3 · converted to months from 45.5 days as posted
ACQ -0.4 vs 0.14 placebo score @ 26wk200/10 mcg BID
absolute change · score
Change from Baseline to Endpoint (week 26)
NCT00383240 · Phase 3
Severe Asthma Exacerbation Occurrence 30.4% (n=191) vs 55.6% (n=196) placebo @ 26wk200/10 mcg BID
event count · % of participants
NCT00383240 · Phase 3 · converted to % from 58 participants as posted
show 1 more result
19.4% (n=155) vs 66.7% (n=129) placebo @ 26wk*100/10 mcg BID
NCT00383552 · Phase 3 · converted to % from 30 participants as posted
FEV1 AUC0-12h 4 vs 1.11 placebo L @ 12wk100/10 mcg BID
absolute change · L
Change from Baseline
NCT00383552 · Phase 3
ACQ Total -0.4 vs -0.11 placebo score @ 26wk100/10 mcg BID
absolute change · score
Change from Baseline
NCT00383552 · Phase 3
AQLQ Total 0.44 vs 0.06 placebo score @ 26wk100/10 mcg BID
absolute change · score
Change from Baseline
NCT00383552 · Phase 3
Night-time Awakening -0.06 vs 0.02 placebo ratio @ 26wk100/10 mcg BID
absolute change · ratio
Change from Baseline
NCT00383552 · Phase 3
FEV1 Trough 0.18 vs 0.04 placebo L @ 12wk100/10 mcg BID
absolute change · L
Change from Baseline
NCT00383552 · Phase 3
FEV1 0.106 L @ 12wk200/10 mcg MDI BID
absolute change · L
No placebo or comparator arm
Change from Baseline in FEV1 at Week 12
NCT01566149 · Phase 3
show 1 more result
0.054 L @ 12wk400/10 mcg MDI BID
Change from Baseline in FEV1 at Week 12
NCT01566149 · Phase 3

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide / formoterol fumarate (SYMBICORT)'s landscape · mometasone furoate/formoterol fumarate's landscape